Services of MTRC

European countries differ substantially in the predictability, speed, evidence burden, and complexity of obtaining reimbursement and enabling routine hospital use of medical devices. This online seminar will present the key findings of the MTRC Reimbursement, Policy & HTA Attractiveness Index 2026, which compares 12 European markets and identifies Germany, Denmark, and Switzerland as the leading markets. It will explain how manufacturers can use the findings to support country prioritization, launch sequencing, evidence planning, and time-to-revenue expectations. The seminar will be delivered by Oleg Borisenko, MD, PhD, on 27 August 2026 at 17:00 CET.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of July 27th, we plan to work on 13 projects. Review the complete list of planned activities in this post.

MTRC is introducing a Market Access Director-for-Hire model in collaboration with Markus Siebert, Partner of MTRC and Head of Metis Market Access Consulting. The model gives MedTech companies flexible access to senior market access leadership to support European launches, internal decision-making, and strategy implementation.

MTRC has opened registration for its free European Market Access Training Program for MedTech professionals, starting on 15 October 2026.

MTRC has released a White Paper titled “PICO in EU Joint Clinical Assessments for Medical Devices: An Overview of the Implications of PICO Scoping for Medical Device Companies.” The White Paper explains the role of the PICO framework in Joint Clinical Assessments under the EU Health Technology Assessment Regulation (EU) 2021/2282.

The book offers a clear and structured introduction to European market access for medical devices, in-vitro diagnostics, and digital health technologies. It explains how reimbursement, payer approval, HTA, evidence requirements, and country-specific adoption pathways influence whether innovative technologies reach patients. Printed copies of Gateway to Europe are available for professionals working in the MedTech, IVD, and digital health technology industries.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of July 13th, we plan to work on 14 projects. Review the complete list of planned activities in this post.

The MTRC team has co-authored a new systematic review and meta-analysis on the diagnostic performance of the MeMed BV test in emergency department and urgent care settings, demonstrating high diagnostic accuracy in distinguishing bacterial infections from viral or other non-bacterial causes, with pooled sensitivity of 91% and specificity of 92%. The paper reflects MTRC’s active involvement in high-quality clinical research, systematic literature reviews, and meta-analyses.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of June 29th, we plan to work on 17 projects. Review the complete list of planned activities in this post.

MTRC has published a new case study showing how a reimbursement application helped a large MedTech company improve funding for an interventional procedure performed in day-case settings in a Nordic country.

MTRC announces the development of a new country ranking framework to support European market access planning for medical device manufacturers. The MedTech EU Market Access Attractiveness Index (MAAI) – Edition 2026 evaluates European countries based on the ease, predictability, and speed of obtaining reimbursement, payment access, and routine hospital use. The Index is designed to help MedTech companies prioritize markets, anticipate access barriers, and align evidence-generation plans with realistic launch and time-to-revenue expectations.

MTRC, together with Markus Siebert of Metis Market Access Consulting, is introducing Market Access Leadership-in-Residence for MedTech and IVD companies. The model provides senior, part-time market access leadership to support European launches, strategic decision-making, team development, and implementation.